Novavax, Inc. NVAX

NVAX Company Overview

Novavax, Inc. is a U.S.-based biotechnology company focused on the research, development, commercialization, and licensing of vaccines for infectious diseases. The company operates within the global biotechnology and vaccine industries, with its primary commercial focus centered on protein-based vaccine technology and adjuvant systems. Novavax’s principal revenue drivers have included sales of its COVID-19 vaccine, licensing agreements, advance purchase arrangements with governments, and strategic collaborations related to vaccine development and manufacturing.

The company is best known for its recombinant nanoparticle vaccine platform and its proprietary Matrix‑M™ adjuvant technology, which is designed to enhance immune response. Novavax has targeted both pandemic and endemic infectious diseases, including COVID-19 and influenza, and has pursued combination vaccine candidates. Founded in 1987 and headquartered in Gaithersburg, Maryland, the company historically operated as a clinical-stage biotechnology firm before transitioning into commercial vaccine distribution during the COVID-19 pandemic. Its strategic positioning has emphasized differentiated protein-based vaccines as alternatives to mRNA technologies, particularly for populations seeking traditional vaccine platforms.